Antiphospholipid Syndrome: The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).Antibodies, Antiphospholipid: Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.Antibodies, Anticardiolipin: Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.beta 2-Glycoprotein I: A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.Lupus Coagulation Inhibitor: An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.Cardiolipins: Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal SYPHILIS SERODIAGNOSIS.Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Catastrophic Illness: An acute or prolonged illness usually considered to be life-threatening or with the threat of serious residual disability. Treatment may be radical and is frequently costly.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Abortion, Habitual: Three or more consecutive spontaneous abortions.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Thrombophilia: A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Antibodies, Neutralizing: Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.Sneddon Syndrome: A systemic non-inflammatory arteriopathy primarily of middle-aged females characterized by the association of livedo reticularis, multiple thrombotic CEREBRAL INFARCTION; CORONARY DISEASE, and HYPERTENSION. Elevation of antiphospholipid antibody titers (see also ANTIPHOSPHOLIPID SYNDROME), cardiac valvulopathy, ISCHEMIC ATTACK, TRANSIENT; SEIZURES; DEMENTIA; and chronic ischemia of the extremities may also occur. Pathologic examination of affected arteries reveals non-inflammatory adventitial fibrosis, thrombosis, and changes in the media. (From Jablonski, Dictionary of Syndromes & Eponymic Diseases, 2d ed; Adams et al., Principles of Neurology, 6th ed, p861; Arch Neurol 1997 Jan;54(1):53-60)Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.Antibody Affinity: A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.Binding Sites, Antibody: Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.Anticoagulants: Agents that prevent clotting.Antibodies, Antinuclear: Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.Pregnancy Complications, Hematologic: The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.Fluorescent Antibody Technique: Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Pregnancy Complications: Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.Epitopes: Sites on an antigen that interact with specific antibodies.Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)Antibodies, Anti-Idiotypic: Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.Skin Diseases, Vascular: Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Partial Thromboplastin Time: The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Abortion, Spontaneous: Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference.Prothrombin: A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.HIV Antibodies: Antibodies reactive with HIV ANTIGENS.Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.Antibodies, Neoplasm: Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.Antibodies, Protozoan: Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.Phospholipids: Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.Lupus Vasculitis, Central Nervous System: Central nervous system vasculitis that is associated with SYSTEMIC LUPUS ERYTHEMATOSUS. Clinical manifestations may include DEMENTIA; SEIZURES; CRANIAL NERVE DISEASES; HEMIPARESIS; BLINDNESS; DYSPHASIA; and other neurological disorders.Pulmonary Embolism: Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.Antigen-Antibody Reactions: The processes triggered by interactions of ANTIBODIES with their ANTIGENS.Fetal Death: Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.Thrombocytopenia: A subnormal level of BLOOD PLATELETS.Panniculitis, Lupus Erythematosus: A type of lupus erythematosus characterized by deep dermal or subcutaneous nodules, most often on the head, face, or upper arms. It is generally chronic and occurs most often in women between the ages of 20 and 45.Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.Plasmapheresis: Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.Blood Coagulation Factors: Endogenous substances, usually proteins, that are involved in the blood coagulation process.Mice, Inbred BALB CAnnexin A5: A protein of the annexin family isolated from human PLACENTA and other tissues. It inhibits cytosolic PHOSPHOLIPASE A2, and displays anticoagulant activity.Immunoglobulin Fab Fragments: Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.Antibodies, Fungal: Immunoglobulins produced in a response to FUNGAL ANTIGENS.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Immunoglobulin A: Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.Annexin A2: A member of the annexin family that is a substrate for a tyrosine kinase, ONCOGENE PROTEIN PP60(V-SRC). Annexin A2 occurs as a 36-KDa monomer and in a 90-KDa complex containing two subunits of annexin A2 and two subunits of S100 FAMILY PROTEIN P11. The monomeric form of annexin A2 was formerly referred to as calpactin I heavy chain.Neutralization Tests: The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).Activated Protein C Resistance: A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)Anetoderma: Benign DERMATOSIS caused by a loss of dermal ELASTIC TISSUE resulting in localized sac-like areas of flaccid skin. It can be either primary (idiopathic) or secondary to other skin conditions, PENICILLAMINE use, or premature birth.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Meningism: A condition characterized by neck stiffness, headache, and other symptoms suggestive of meningeal irritation, but without actual inflammation of the meninges (MENINGITIS). Spinal fluid pressure may be elevated but spinal fluid is normal. (DeJong, The Neurologic Examination, 4th ed, p673)Antibodies, Bispecific: Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.Phosphatidylserines: Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.Single-Chain Antibodies: A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.Heparin, Low-Molecular-Weight: Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.Antibodies, Blocking: Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)Thrombophlebitis: Inflammation of a vein associated with a blood clot (THROMBUS).Trophoblasts: Cells lining the outside of the BLASTOCYST. After binding to the ENDOMETRIUM, trophoblasts develop into two distinct layers, an inner layer of mononuclear cytotrophoblasts and an outer layer of continuous multinuclear cytoplasm, the syncytiotrophoblasts, which form the early fetal-maternal interface (PLACENTA).Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.Blood Coagulation: The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.Myelitis, Transverse: Inflammation of a transverse portion of the spinal cord characterized by acute or subacute segmental demyelination or necrosis. The condition may occur sporadically, follow an infection or vaccination, or present as a paraneoplastic syndrome (see also ENCEPHALOMYELITIS, ACUTE DISSEMINATED). Clinical manifestations include motor weakness, sensory loss, and incontinence. (Adams et al., Principles of Neurology, 6th ed, pp1242-6)Eclampsia: Onset of HYPERREFLEXIA; SEIZURES; or COMA in a previously diagnosed pre-eclamptic patient (PRE-ECLAMPSIA).Antibodies, Heterophile: Antibodies elicited in a different species from which the antigen originated. These antibodies are directed against a wide variety of interspecies-specific antigens, the best known of which are Forssman, Hanganutziu-Deicher (H-D), and Paul-Bunnell (P-B). Incidence of antibodies to these antigens--i.e., the phenomenon of heterophile antibody response--is useful in the serodiagnosis, pathogenesis, and prognosis of infection and latent infectious states as well as in cancer classification.Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.Gangrene: Death and putrefaction of tissue usually due to a loss of blood supply.Antibodies, Catalytic: Antibodies that can catalyze a wide variety of chemical reactions. They are characterized by high substrate specificity and share many mechanistic features with enzymes.Heparin: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Factor V: Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.Immunoassay: A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.HELLP Syndrome: A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.Endocarditis: Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Adrenal Insufficiency: Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.Pregnancy Outcome: Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; SPONTANEOUS ABORTION; INDUCED ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.Blue Toe Syndrome: A condition that is caused by recurring atheroembolism in the lower extremities. It is characterized by cyanotic discoloration of the toes, usually the first, fourth, and fifth toes. Discoloration may extend to the lateral aspect of the foot. Despite the gangrene-like appearance, blue toes may respond to conservative therapy without amputation.Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Lupus Nephritis: Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Autoantigens: Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Fluorescent Antibody Technique, Indirect: A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)Hybridomas: Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Immune Sera: Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Epitope Mapping: Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.Immunoglobulins: Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.Infarction: Formation of an infarct, which is NECROSIS in tissue due to local ISCHEMIA resulting from obstruction of BLOOD CIRCULATION, most commonly by a THROMBUS or EMBOLUS.Complement System Proteins: Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).Anemia, Hemolytic, Autoimmune: Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.Prenatal Injuries: Damages to the EMBRYO, MAMMALIAN or the FETUS before BIRTH. Damages can be caused by any factors including biological, chemical, or physical.International Normalized Ratio: System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.Copying Processes: Reproduction of data in a new location or other destination, leaving the source data unchanged, although the physical form of the result may differ from that of the source.Antigens: Substances that are recognized by the immune system and induce an immune reaction.Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Protein Binding: The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Puerperal Disorders: Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.Complement Activation: The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES.Binding, Competitive: The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Immunoglobulins, Intravenous: Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.

Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. (1/452)

Antiphospholipid antibodies (aPL), anti-beta 2-glycoprotein I (anti-beta 2-GPI) and anti-oxidized-low-density lipoprotein (LDL) antibodies are all implicated in the pathogenesis of antiphospholipid syndrome. To investigate whether different autoantibodies or combinations thereof produced distinct effects related to their antigenic specificities, we examined the frequencies of antiphospholipid syndrome (APS)-related features in the presence of different antibodies [aPL, beta 2-GPI, anti-oxidized low density lipoprotein (LDL)] in 125 patients with APS. Median follow-up was 72 months: 58 patients were diagnosed as primary APS and 67 as APS plus systemic lupus erythematosus (SLE). Anticardiolipin antibodies (aCL), anti-beta 2-GPI and anti-oxidized LDL antibodies were determined by ELISA; lupus anticoagulant (LA) by standard coagulometric methods. Univariate analysis showed that patients positive for anti-beta 2-GPI had a higher risk of recurrent thrombotic events (OR = 3.64, 95% CI, p = 0.01) and pregnancy loss (OR = 2.99, 95% CI, p = 0.004). Patients positive for anti-oxidized LDL antibodies had a 2.24-fold increase in the risk of arterial thrombosis (2.24, 95% CI, p = 0.03) and lower risk of thrombocytopenia (OR = 0.41 95% CI, p = 0.04). Patients positive for aCL antibodies had a higher risk of pregnancy loss (OR = 4.62 95% CI, p = 0.001). When these data were tested by multivariate logistic regression, the association between anti-beta 2-GPI and pregnancy loss and the negative association between anti-oxidized LDL antibodies and thrombocytopenia disappeared.  (+info)

Antibodies against phospholipids and oxidized LDL in alcoholic patients. (2/452)

Antiphospholipid antibodies (APA) are a generic term describing antibodies that recognize various phospholipids. Hepatocyte damage is a cardinal event in the course of alcoholic liver injury and autoantibodies against phospholipids could play an important role in this process. APA in alcoholic patients seem to reflect membrane lesions, impairment of immunological reactivity, liver disease progression and they correlate significantly with disease severity. LDL oxidation is supposed to be one of the most important pathogenic mechanisms of atherosclerosis and antibodies against oxidized low-density lipoprotein (oxLDL) are some kind of an epiphenomenon of this process. The scope of our study was to determine some autoantibodies (IgG-oxLDL and antiphospholipid antibodies) and their possible changes in alcoholic patients. We studied IgG-oxLDL and four APA - anticardiolipin antibodies (ACA), antiphosphatidylserine antibodies (APSA) antiphosphatidylethanolamine antibodies (APE) and antiphosphatidylcholine antibodies (APCA) in 35 alcoholic patients with mildly affected liver function at the beginning of the abuse treatment. The control group consisted of 60 healthy blood donors. In the studied group, we obtained positive results concerning total ACA in 17.1 % of alcoholic patients (8.3 % in the control group), 11.4 % IgG-ACA (6.7 %), 8.6 % IgM-ACA (3.3 %), 14.3 % total APE (6.7 %), 14.3 % total APCA (8.3 %) and 20 % total APSA (8.3 % in the control group). The IgG-oxLDL (406.4+/-52.5 vs 499.9+/-52.5 mU/ml) was not affected in alcoholic patients. We conclude that the autoantibodies against oxLDL are present in sera of alcoholics and healthy blood donors. Based on our results which revealed a wide range of IgG-oxLDL titres in the healthy population, this parameter does not appear to be very promising for the evaluation of the risk of atherosclerosis. Alcoholics with only mild affection of liver functions did not exhibit a significantly higher prevalence of all studied antiphospholipid antibodies (ACA, APSA, APE, APCA) which could lead to membrane lesions in these patients.  (+info)

The intrarenal vascular lesions associated with primary antiphospholipid syndrome. (3/452)

Even 10 yr after the identification of the antiphospholipid syndrome (APS), renal involvement in the course of APS is still relatively unrecognized, and is probably underestimated. The association of anticardiolipin antibodies and/or lupus anticoagulant with the development of a vaso-occlusive process involving numerous organs is now confirmed. In a multicenter study, 16 cases of "primary" APS (PAPS) were found and followed for 5 yr or more, all with renal biopsy. In all 16 cases of PAPS, there was a vascular nephropathy characterized by small vessel vaso-occlusive lesions associated with fibrous intimal hyperplasia of interlobular arteries (12 patients), recanalizing thrombi in arteries and arterioles (six patients), and focal cortical atrophy (10 patients). In combination, these led to progressive destruction of the kidney, accelerated by acute glomerular and arteriolar microangiopathy in five patients. Focal cortical atrophy is a distinctive lesion, present in 10 biopsies, and likely represents the histologic and functional renal analogue to the multiple cerebral infarcts detected on imaging studies. The clinical hallmark of this vascular nephropathy in PAPS is systemic hypertension, only variably associated with renal insufficiency, proteinuria, or hematuria. The ensemble of histologic renal lesions defined in this study should aid in the separation of the lesions found in cases of secondary APS, especially systemic lupus erythematosus, into those lesions related to APS and those related to the underlying disease.  (+info)

Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion. (4/452)

We describe the case of a 39-year-old woman who suffered two iliofemoral venous thromboses, a cerebral ischemic infarct and recurrent fetal loss. Initial studies showed high levels of antiphospholipid antibodies (APAs) and a moderate thrombocytopenia. After her second miscarriage, laboratory diagnosis revealed that the woman was heterozygous for the factor V Leiden mutation and had a functional protein S deficiency as well as anti-protein S and anti-beta 2-glycoprotein I antibodies. The impairment of the protein C pathway at various points could well explain the recurrent thromboses in the patient and supports the role of a disturbed protein C system in the pathophysiology of thrombosis in patients with APAs.  (+info)

Anti-phospholipid antibodies and CD5+ B cells in HIV infection. (5/452)

This cross-sectional study evaluates the correlation between anti-phospholipid antibodies and CD5+ B cells in 110 patients infected with HIV-1. There were 89.1% of the patients who had IgG antibodies against cardiolipin and phosphatidylserine. The prevalence of IgM and IgA antibodies was < 22%. AIDS was associated with lower frequencies of IgM antibodies against cardiolipin (P = 0.05) and IgG-antibodies against cardiolipin and phosphatidylserine (P = 0.011). Drug users had higher IgM antibodies against phospholipids than patients from other risk groups (P = 0.02). A history of thromboembolic events was not accompanied by higher levels of anti-phospholipid antibodies (P > 0.2). No correlation between anti-phospholipid antibodies and CD5+ B cells was detected. Percentage part of CD5+ B lymphocytes was elevated in all patients and absolute CD4+ T lymphocyte counts and HIV p24 antigen were inversely correlated. In advanced disease a significant reduction of anti-phospholipid antibodies was contrasted with persistent elevation of CD5+ B lymphocytes. These observations may reflect immunological dysfunction involving apoptosis and endothelial damage rather than polyclonal B cell hyperstimulation. A possible explanation would be that in HIV infection an increased rate of spontaneous apoptosis in peripheral blood lymphocytes is accompanied by functional and structural changes of mitochondria. Therefore, structurally altered mitochondrial phospholipids could serve as antigen to induce specific humoral immune responses.  (+info)

Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. (6/452)

Cardiovascular manifestations are common in systemic lupus erythematosus (SLE). Oxidized low-density lipoprotein (oxLDL) is implicated in cardiovascular disease, especially atherosclerosis, and cross-reacts with antibodies to cardiolipin (aCL). beta 2-GPI is a plasma protein participating in the coagulating cascade, and is also cofactor for aCL, and some aCL have been shown to be directed against beta 2-GPI and/or complexes between beta 2-GPI and phospholipids. Lysophosphatidylcholine (LPC) is a phospholipid present both in oxLDL and in damaged endothelium, and we recently showed that LPC is involved in the antigenicity of oxLDL. Antibodies to endothelial cells (aEC) correlate with diseases activity in SLE and vasculitis, and we recently showed that aEC are enhanced in cardiovascular disease such as borderline hypertension and early atherosclerosis. aEC were determined using EC from adult V. Saphena Magna. Antibody levels were determined by ELISA. aEC of IgG type were enhanced in 184 patients with SLE compared with 85 healthy controls. There was a close correlation between aoxLDL, aCL, aLPC, a beta 2-GPI and aEC. Binding of sera to EC was competitively inhibited by beta 2-GPI, LPC and oxLDL. Taken together, the data indicate that EC share antigenic epitopes with beta 2-GPI and with oxLDL, especially LPC. Phospholipids in EC membranes may thus be antigenic epitopes. beta 2-GPI may bind to these phospholipids, and become an autoantigen. LPC is formed by oxidation of phospholipids and/or proinflammatory factors leading to activation of phospholipase A2, and the findings indicate the potential role of both lipid oxidation and phospholipase A2 in SLE.  (+info)

The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. (7/452)

OBJECTIVES: The impact of infection-associated antiphospholipid antibodies (APA) on endothelial cell activation, blood coagulation and fibrinolysis was evaluated in patients with infective endocarditis with and without major embolic events. BACKGROUND: An embolic event is a common and severe complication of infective endocarditis. Despite the fact that APAs are known to be associated with infectious diseases, their pathogenic role in infective endocarditis has not been clearly defined. METHODS: The relationship among the occurrence of major embolic events, echocardiographic vegetation size, endothelial cell activation, thrombin generation, fibrinolysis and APA was examined in 91 patients with definite infective endocarditis, including 26 patients with embolic events and 65 control subjects without embolic events. RESULTS: Overall, 14.3% of patients exhibited elevated APA levels. Embolic events occurred more frequently in patients with elevated levels of APA than in patients without (61.5% vs. 23.1%; p = 0.008). Patients with elevated levels of APA showed higher levels of prothrombin-fragment F1 +2 (p = 0.005), plasminogen-activator inhibitor 1 (p = 0.0002), von Willebrand factor (p = 0.002) and lower levels of activated protein C (p = 0.001) than patients with normal levels of APA. Thrombin generation and endothelial cell activation were both positively correlated with levels of APA. The occurrence of elevated APA levels was frequently associated with structural valve abnormalities (p = 0.01) and vegetations >1.3 cm (p = 0.002). CONCLUSIONS: Infection-associated elevated APA levels in patients with infective endocarditis are related to endothelial cell activation, thrombin generation and impairment of fibrinolysis. This may contribute to the increased risk for major embolic events in these patients.  (+info)

Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. (8/452)

BACKGROUND: Antiphospholipid (aPL) antibodies are associated with thrombosis in patients diagnosed with antiphospholipid syndrome (APS) and enhance thrombus formation in vivo in mice, but the mechanism of thrombosis by aPL is not completely understood. Although aPL antibodies have been shown to inhibit protein C activation and activate endothelial cells (ECs) in vitro, no study has examined whether these antibodies activate ECs in vivo. Therefore, human affinity-purified aPL (ap aPL) antibodies from APS patients were tested in a mouse model of microcirculation using the cremaster muscle that allows direct microscopic examination of thrombus formation and adhesion of white blood cells (WBCs) to ECs as an indication of EC activation in vivo. Adhesion molecule expression on human umbilical vein endothelial cells (HUVECs) after aPL exposure was performed to confirm EC activation in vitro. METHODS AND RESULTS: All 6 ap aPL antibodies significantly increased the expression of VCAM-1 (2.3- to 4.4-fold), with one of the antibodies also increasing the expression of E-selectin (1.6-fold) on HUVECs in vitro. In the in vivo experiments, each ap aPL antibody except for 1 preparation increased WBC sticking (mean number of WBCs ranged from 22.7 to 50.6) compared with control (14.4), which correlated with enhanced thrombus formation (mean thrombus size ranged from 1098 to 6476 versus 594 microm2 for control). CONCLUSIONS: Activation of ECs by aPL antibodies in vivo may create a prothrombotic state on ECs, which may be the first pathophysiological event of thrombosis in APS.  (+info)

*Antiphospholipid syndrome

... is an autoimmune disease, in which "antiphospholipid antibodies" (anticardiolipin antibodies and ... Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused ... The presence of antiphospholipid antibodies (aPL) in the absence of blood clots or pregnancy-related complications does not ... Clinically important antiphospholipid antibodies (those that arise as a result of the autoimmune process) are associated with ...

*Systemic lupus erythematosus

Abnormalities associated with antiphospholipid antibody syndrome include a paradoxical prolonged partial thromboplastin time ( ... Ünlü, O; Zuily, S; Erkan, D (2016). "The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus ... These antibodies clump into antibody-protein complexes which stick to surfaces and damage blood vessels in critical areas of ... People with SLE may have an association with antiphospholipid antibody syndrome (a thrombotic disorder), wherein autoantibodies ...

*Recurrent miscarriage

Around 15% of the women who have recurrent miscarriages have high levels of antiphospholipid antibodies. Women who have had ... may have their blood tested for antibodies, to determine if they have antiphospholipid syndrome. Women diagnosed with ... "Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant". Cochrane Database of ... The antiphospholipid syndrome is an autoimmune disease that is a common cause of recurrent pregnancy loss. ...

*Lupus anticoagulant

... as well as serological testing to identify common autoantibodies such as antiphospholipid antibodies. These antibodies tend to ... Current evidence suggests that the risk of recurrent thrombosis in patients with an antiphospholipid antibody is enhanced ... "Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant" (PDF). The Cochrane ... Lupus anticoagulant antibodies in living systems cause an increase in inappropriate blood clotting. The name derives from their ...

*Systemic lupus erythematosus and pregnancy

... are recommended to be screened for antiphospholipid antibodies, both the lupus anticoagulant (the RVVT and sensitive PTT are ... Women pregnant and known to have anti-Ro (SSA) or anti-La antibodies (SSB) often have echocardiograms during the 16th and 30th ... Later losses appear to occur primarily due to the antiphospholipid syndrome, in spite of treatment with heparin and aspirin. ... the best screening battery) and anticardiolipin antibodies. Neonatal lupus is the occurrence of SLE symptoms in an infant born ...

*Amaurosis fugax

"Amaurosis fugax associated with antiphospholipid antibodies". Annals of Neurology. 25 (3): 228-32. doi:10.1002/ana.410250304. ... syndromePolycythemia HypercoagulabilityProtein C deficiency Antiphospholipid antibodiesAnticardiolipin antibodies Lupus ... "Transient visual symptoms in systemic lupus erythematosus and antiphospholipid syndrome". Ocul. Immunol. Inflamm. 9 (1): 49-57 ...

*EVA1A

"Genome-wide association study of antiphospholipid antibodies". Autoimmune Diseases. 2013: 761046. doi:10.1155/2013/761046. PMC ...

*Parvovirus B19

Human parvovirus B19 infection and antiphospholipid antibodies, 2006 G. Siegl and P. Cassinotti, Parvoviruses Chapter 14, ... Human parvovirus B19 infection and antiphospholipid antibodies , 2006. "Other Types of Arthritis". Arthritis Action UK. ... VP1-proteins are incorporated into the capsid structure in a non-stochiometrical relation (based on antibody-binding analysis ... Individuals with B19 IgG antibodies are generally considered immune to recurrent infection, but reinfection is possible in a ...

*Cerebritis

These antibodies are seen in 90% of SLE patients with psychosis. Antiphospholipid antibodies. The two antibodies implicated are ... "Anti-neuronal Antibodies". Retrieved 2010-04-20. "Antiphospholipid Antibodies". Retrieved 2010-04-20. "Cytokine Release". ... Anti-neuronal antibodies. The three identified anti-neuronal antibodies postulated in CNS involvement are the lympho-cytotoxic ... These antibodies also correlate with cognitive and visual spatial defects. Second, the anti-neuronal membrane antibodies are ...

*Anti-apolipoprotein antibodies

However, antiphospholipid antibodies bind phospholipids at sites similar to sites bound by anti-coagulants such as PAP1 sites ... Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RF (1993). "Effect of antiphospholipid antibodies on procoagulant activity of ... Sammaritano LR, Gharavi AE, Soberano C, Levy RA, Lockshin MD (1992). "Phospholipid binding of antiphospholipid antibodies and ... In autoimmune disease, anti-apolipoprotein H (AAHA) antibodies, also called anti-β2 glycoprotein I antibodies, comprise a ...

*Anti-cardiolipin antibodies

1985). "Crossreactivity of antiphospholipid antibodies". Journal of clinical & laboratory immunology. 16 (1): 1-6. PMID 3981615 ... They are a form of anti-mitochondrial antibody. In SLE, anti-DNA antibodies and anti-cardiolipin antibodies may be present ... McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990). "Anti-phospholipid antibodies are directed against a complex antigen ... Anti-cardiolipin antibodies (ACA) are antibodies often directed against cardiolipin and found in several diseases, including ...

*Paul Stelzer

Anticoagulation Management in a Patient With Antiphospholipid Antibodies Requiring Repeat Sternotomy. J Cardiothorac Vasc ...

*Lupus headache

Annese V, Tomietto P, Venturini P, D'Agostini S, Ferraccioli G (2006). "[Migraine in SLE: role of antiphospholipid antibodies ... headaches in SLE and associated Raynaud's phenomenon and/or anti-cardiolipin antibodies. Further studies are needed however to ...

*David L. Reich

"Anticoagulation Management in a Patient With Antiphospholipid Antibodies Requiring Repeat Sternotomy. J Cardiothorac Vasc ...

*Autosplenectomy

Santilli, Daniele (2003). "Autosplenectomy and Antiphospholipid Antibodies in Systemic Lupus Erythematosus: A Pathogenic ...

*Michael D. Lockshin

... and many research papers on the antiphospholipid antibody syndrome. He convened the first International Conference on Pregnancy ... He is a researcher of autoimmune diseases, with focus on antiphospholipid syndrome and lupus. He is currently Professor of ... Lockshin's long-term research interest is in the clinical aspects of systemic lupus erythematosus (SLE), antiphospholipid ...

*MYD88

"Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies". Blood. 101 (9): ...

*Nonsteroidal anti-inflammatory drug

Aspirin, however, is used together with heparin in pregnant women with antiphospholipid antibodies. Additionally, indomethacin ... Cervera R, Balasch J (2004). "The management of pregnant patients with antiphospholipid syndrome". Lupus. 13 (9): 683-7. doi: ...

*Sneddon's syndrome

About 40-60% of patients with the syndrome test positive for antiphospholipid antibodies. Sneddon's patients are generally ... Sneddon's Syndrome was formerly understood to be a type of autoimmune disease called antiphospholipid syndrome, although it has ...

*Miscarriage

A disruption in normal immune function can lead to the formation of antiphospholipid antibody syndrome. This will effect the ...

*Ischemic optic neuropathy

Such as juvenile diabetes mellitus, antiphospholipid antibody-associated clotting disorders, collagen-vascular disease, and ...

*Annexin A5

In the antiphospholipid antibody syndrome, the formation of the shield is disrupted by antibodies. Without the shield, there is ... Antibodies directed against annexin A5 are found in patients with a disease called the antiphospholipid syndrome (APS), a ... speeding up coagulation reactions and causing the blood-clotting characteristic of the antiphospholipid antibody syndrome. ...

*Single colour reflectometry

2014). Diagnostic performance study of an antigen microarray for the detection of antiphospholipid antibodies in human serum. ... antibodies. Binding of specific ligands to the immobilised receptor molecules results in a change refractive index n and ...

*Thrombotic storm

Acute multi-organ failure associated with antiphospholipid antibodies: A review of 31 patients". Lupus. 5 (5): 414-7. doi: ... Triplett, Douglas A.; Asherson, Ronald A. (2000). "Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS)". ... Asherson, RA; Piette, JC (1996). "The catastrophic antiphospholipid syndrome 1996: ... other than Antiphospholipid syndrome) Treatment for Thrombotic Storm may include lifelong anticoagulation therapy and/or ...

*Wassermann test

Syphilis non-specific antibodies (reagin, see RPR) react with the lipid - the Wassermann reaction of antiphospholipid ... The antibody test was developed by Wassermann, Julius Citron, and Albert Neisser at the Robert Koch Institute for Infectious ... The Wassermann test or Wassermann reaction (WR) is an antibody test for syphilis, named after the bacteriologist August Paul ... antibodies (APAs). The intensity of the reaction (classed 1, 2, 3, or 4) indicates the severity of the condition. The reaction ...

*Matthew H. Liang

In the Physicians' Health Study, they provided the first convincing evidence that the antiphospholipid antibody was a risk ...

*Annexin

Rand JH (September 2000). "Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic ... In such cases, antibodies against annexin A-V destroy its 2-dimensional crystal structure and uncover the phospholipids in the ... Through antibody recognition, there is evidence of the annexin like proteins being involved in the positioning and attachment ... be used as a cell surface protein to mark some forms of tumors that can be targeted by various immunotherapies with antibodies ...
Autori: Tanaseanu C., Moldoveanu E., Tanaseanu S., Popescu L.M.. Editorial: Haematologia, 31(4), p.287-302, 2002.. Rezumat:. Abstract: Antiphospholipid antibodies (APLAs) are a group ol autoantibodies directed against certain phospholipids, or their protein cofactors. Assay of APLAs is important because their interaction with anionic phospholipid-protein cofactors can generate a syndrome of hypercoagulability associated with a wide variety of thromboembolic events. This article presents the characteristics of some APLAs [anticardiolipin antibodies (aCLAs), lupus anticoagulant (LA) and anti-beta2-glycoprotein I antibodies (anti-beta2-GPIAs)], their action, and their interaction with blood and endothelial cells. The presence of APLAs has been reported in many diseases (autoimmune diseases, atherosclerosis, infections, malignancies), being related to pathogenic mechanisms and/or to a more severe evolution of the disease.. Cuvinte cheie: antiphospholipid antibodies, antiphospholipid syndrome, ...
Recurrent miscarriage (RM) is traditionally defined as three or more consecutive miscarriages occurring before 20 weeks post-menstruation. It is one of the most common clinical problems in reproduction, yet a definite cause can be established in only 50 percent of cases (ACOG practice bulletin, 2002). Many etiological factors have been proposed but none of them has been fully substantiated. RM has been directly associated with maternal thrombophilic disorders, parental chromosomal anomalies, and structural uterine anomalies and indirectly with maternal immune dysfunction and endocrine abnormalities.. The association between pregnancy loss and antiphospholipid antibodies (aPL) was first noticed in the latter third of the last century. The antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (APLA), associated with venous and/or arterial thrombosis, and/or pregnancy loss. The adverse pregnancy outcomes associated with the presence of APLAs include: ...
Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. The investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities ...
You may also need to take blood thinners for 3 to 4 weeks after surgery to lower your risk of blood clots.. ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS) In general, you will need long-term treatment with a blood thinner for a long time if you have the APS. Initial treatment may be heparin, either unfractionated or low-molecular heparin. These medicines are given by injection.. In most cases, warfarin (Coumadin), which is given by mouth, is then started. It is necessary to monitor the level of anticoagulation frequently. This is most often done using the INR test.. If you have APS and become pregnant, you will need to be followed closely by a provider expert in this condition. You will not take warfarin during pregnancy, but will be given low-molecular weight heparin instead.. If you have SLE and APS your provider will also recommend that you take hydroxychloroquine. ...
Methods Patients with a history of positive antiphospholipid antibodies and neuropsychiatric symptoms but without thromboembolism composed the case group; patients without antiphospholipid antibody served as the control group. Subjects with autoantibodies to extractable nuclear antigens were excluded from this study. All patients underwent Tc-99m ECD SPECT and were classified by the number of positive antiphospholipid antibodies they carried. The heterogeneity of brain perfusion was defined as the coefficient of variation. Analysis of variance (ANOVA) was used to evaluate the differences between groups. ...
Summary Antiphospholipid antibodies (APLA) have been shown to activate endothelial cells (EC) in vitro, as documented by an increased expression of tissue factor as well as leukocyte adhesion molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule (VCAM)-1 and E-selecti...
Read "Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia, Scientific Reports" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Autori: Tanaseanu CM, Moldoveanu E, Tanaseanu S, Marta DS, Manea G, Tamsulea I, Popescu M, Dumitrascu A, Kosaka T, Grecu V, Uscatescu V. Editorial: Annals of The Rheumatic Diseases, 64 Suppl. 3, p.246, 2005.. Rezumat:. Cuvinte cheie: Antiphospholipid antibodies, vascular endothelial growth factor, P-selectin, lipoprotein-associated phospholipase-A2, pulmonary arterial hypertension ...
Methods We identified all patients with ESRD at our center who had aPL Abs measured between 2005 and 2012. SLE was defined using ICD9 (International Classification of Disease) code (710.0). We also determined the prevalence of aPL Abs in a subgroup of patients who fulfilled the American College of Rheumatology criteria for SLE and had a history of biopsy proven lupus nephritis. IgA, IgG, and IgM isotypes were measured for the following aPL Abs: anticardiolipin (aCL), anti-beta2 glycoprotein I (anti-B2GPI), and antiphosphatidylserine (aPS). Positivity was defined as ≥20IU ("laboratory criteria"), and ≥40IU ("clinical criteria"). We used Fisher exact test to compare the frequencies of aPL Abs between non-SLE, SLE by ICD9 and SLE by ACR criteria vs. non-SLE.. ...
We report in Figure 2 the annual rate (∼ 0.4%) of first cardiovascular event (including VTE) in normal white population at 35 to 55 years of age,14 that (1.36%) of 125 single aPL positive carriers with a mean age of 41 years (data taken by a recently published study by our group),15 and that (5.3%) of triple-positive carriers of this study (mean age, 45 years). Annual rate in a cohort of SLE patients half of whom had aPL was 2.9 per 100 patient-years.16 Hence, because less than half of our cohort had autoimmune disorders, the higher incidence of TEs recorded in this study may be related to the selection of high-risk aPL-positive population. Likewise, in patients with APS and triple positivity,7 TEs were equally distributed among arterial and venous circulation. Some patients in this study were treated with aspirin for primary thromboprophylaxis, behavior that did not lead to a significant reduction of events. To our knowledge, only one prospective clinical trial addresses the question of ...
Am J Reprod Immunol. 2009 Aug;62(2):96-111. doi: 10.1111/j.1600-0897.2009.00717.x. Research Support, N.I.H., Extramural; Research Support, Non-U.S. Govt
We evaluated inter-assay variation in anticardiolipin antibody status, comparing three centres, and using different assays among 36 women with recurrent miscarriage and 26 controls. There was no more agreement between the laboratories than would be predicted on the basis of chance for IgM and only fair agreement among the laboratories for IgG. None of the tests were significantly more likely to be positive in the cases compared with the controls ...
An examination of the symptoms, rupture of blood cells (fibrin production), liver damage, clotting (low serum heparin), high blood pressure (capillary apoptosis), proteinuria (low heparan sulfate (HS) to prevent protein loss), pointed to some obvious treatments and the causes. Infertility is often treated by in vitro fertilization/insemination, supported with aspirin and heparin injections to maintain gestation. These treatments are consistent with high levels of chronic inflammation that block implantation and stimulate labor. Infertility is also associated with antiphospholipid antibodies. A closer look at the antiphospholipid antibodies showed that they were directed against β2-glycoprotein-I. So, I expected the β2-glycoprotein-I protein to be the original target for the antibodies, the initiating antigen, but when I looked up the sequence of that protein, it lacked the expected basic triplet I have found in all other autoantigens and allergens. This meant to me that there was a different ...
Hepatitis C, a worldwide viral infection, is an important health problem in Brazil. The virus causes chronic infection, provoking B lymphocyte dysfunction, as represented by cryoglobulinemia, non-organ-specific autoantibody production, and non-Hodgki
O Machine Pineapple Core (1) 10 Weeks (20) 100 Followers Giveaway Celebration (12) 10dpo (3) 11 Weeks (15) 11dpo (1) 11w6d (1) 12 Weeks (20) 12dpo (2) 12w2d (1) 13 Weeks (11) 13w1d (2) 14 Weeks (14) 15 Weeks (12) 16 DPO (1) 16 Weeks (13) 17 Weeks (15) 18 Weeks (10) 19 Weeks (14) 1st Cycle TTC (19) 1st Trimester (33) 20 Weeks (14) 21 Weeks (8) 22 Weeks (6) 23 Weeks (11) 24 Weeks (11) 25 Weeks (10) 26 weeks (8) 27 Weeks (10) 28 Weeks (10) 29 Weeks (8) 2dp5dt (1) 2nd Trimester (55) 2WW (111) 3 Weeks 1 Day (1) 30 Weeks (10) 31 Weeks (8) 32 Weeks (8) 33 Weeks (12) 34 Weeks (6) 34w5d (1) 35 Weeks (9) 35 Weeks 2 days (1) 35/35 (4) 36 Weeks (8) 37 Weeks (9) 38 Weeks (4) 39 Weeks (2) 3DPO (1) 3dt v 5dt (1) 3rd Trimester (43) 3TC (1) 4 weeks pg (19) 40 Weeks (3) 4w4d (1) 4w6d (1) 5 weeks (14) 5DT (3) 5w2d (1) 6 weeks (19) 6 weeks 1 day (2) 6w2d (2) 6w5d (1) 7 weeks (17) 7DPO (2) 8 DPO (1) 8 weeks (19) 8w2d (2) 9 Weeks (13) 9DPO (3) 9w1d (1) 9w3d (1) Abnormal Pap (1) Accessorize (1) Acronyms (1) ...
Always interesting to read this blog even if the science is more often than not beyond me. Like a lot of people who read these posts, theyve probably arrived here trying to find a solution to ill health that their doctors have failed to solve. In my situation I have had both chronic rhinitis which gives me nocturnal headaches and a generalised inflammation in the pelvic area, never properly diagnosed beyond being told that I have Pelvic pain syndrome. 15 years of burning, ED and headaches is no fun! As I trawl the net looking for advice one comes across all sorts of suggestions for good health. Prof Ayers protocol is one. My question is how can we know that this is correct? For example I recently came across Dr McDougals Starch Solution, a low protein, very low fat, very high starch diet. Anecdotally, many people have responded well to this diet, losing weight (not a problem for me, I am skinny) and more interestingly for me, finding long standing health issues, including inflammation, ...
Always interesting to read this blog even if the science is more often than not beyond me. Like a lot of people who read these posts, theyve probably arrived here trying to find a solution to ill health that their doctors have failed to solve. In my situation I have had both chronic rhinitis which gives me nocturnal headaches and a generalised inflammation in the pelvic area, never properly diagnosed beyond being told that I have Pelvic pain syndrome. 15 years of burning, ED and headaches is no fun! As I trawl the net looking for advice one comes across all sorts of suggestions for good health. Prof Ayers protocol is one. My question is how can we know that this is correct? For example I recently came across Dr McDougals Starch Solution, a low protein, very low fat, very high starch diet. Anecdotally, many people have responded well to this diet, losing weight (not a problem for me, I am skinny) and more interestingly for me, finding long standing health issues, including inflammation, ...
A research group from University College Londons (UCL) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to advance the development of a novel treatment for anti-phospholipid syndrome (APS) based on Abzenas conjugation technology.. APS is a disorder of the immune system, where abnormal antibodies, called antiphospholipid antibodies (aPL) are produced. These bind to beta-2-glycoprotein (beta-2-GPI) in the blood and increase the risk of clotting. Patients with APS are more likely to have a stroke or heart attack and pregnant women with APS have an increased risk of recurrent miscarriage.. The condition can occur on its own or alongside other autoimmune disorders. Patients are currently treated with anticoagulants, such as warfarin, but these are associated with a significant risk of bleeding so there is a need for alternative therapies.. Abzena has a longstanding collaboration with Professor Anisur Rahman and his team at UCL who identified that an ...
Health, ...For years researchers have known that antiphospholipid antibodies (aP... Based on the available data our best estimate is that around 10 to 1...The research will be presented on Nov. 13 at 3:15 p.m. ET during the...In some individuals aPLs do not cause any health problems but in oth...,Autoimmune,disease,linked,to,pregnancy,loss,,stroke,more,often,than,you d,expect,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
If you are a paid subscriber to HDCN, the full text of this review article is available to you for download. Please RIGHT CLICK on the link that follows, and then use File-Save-As to save the .PDF file to your computer, where you can open the file using Acrobat Reader. Left clicking on the linkwill also work if Acrobat Reader has been integrated into your browser. Click here for .PDF file ...
Question - Pregnant, US showed low lying posterior. History of miscarriage. Was positive for APTT and APLA, started Heparin. Ask a Doctor about diagnosis, treatment and medication for Thrombosis, Ask an OBGYN, Gynecologic Oncology
Antiphospholipid antibody syndrome: Find the most comprehensive real-world symptom and treatment data on antiphospholipid antibody syndrome at PatientsLikeMe. 640 patients with antiphospholipid antibody syndrome experience fatigue, Pain, depressed mood, anxious mood, and insomnia and use Aspirin, Hydroxychloroquine, Warfarin, Enoxaparin, and Oxycodone to treat their antiphospholipid antibody syndrome and its symptoms.
Systemic Antiphospholipid Syndrome, Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid Syndrome - Systemic Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory abnormalities. These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS. Unfortunately, some synonyms can be confusing. Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory
Systemic Antiphospholipid Syndrome, Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid Syndrome - Systemic Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory abnormalities. These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS. Unfortunately, some synonyms can be confusing. Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory
Donadini, MP, Crowther, M. "Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestations". Hematol-Oncol. vol. 24. 2010. pp. 669-76. (Recent concise review and update of this syndrome. Many of the clinical statistics were cited from this review.). Ruiz-Irastorza, G, Crowther, M, Branch, W, Khamashta, MA. "Antiphospholipid syndrome". Lancet. vol. 376. 2010. pp. 1498-1509. (Along with the first listed reference, a key source for this chapter, especially with respect to treatment recommendations.). Frances, C. "Dermatological manifestations of Hughes antiphospholipid antibody syndrome". Lupus. vol. 19. 2010. pp. 1071-77. (Current review of cutaneous manifestations.). Weinstein, S, Piette, W. "Cutaneous manifestations of antiphospholipid antibody syndrome". Hematol Oncol Clinics N Am. vol. 22. 2008. pp. 67-77. (Relatively recent review of cutaneous findings.). Hughes, GRV. "Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics". Lupus. vol. 19. 2010. pp. ...
Antiphospholipid antibody syndrome is a fascinatingly complex disorder. It is an autoimmune disease, whereby the immune system attacks our own tissues. This article summarises the basic mechanisms of the condition and main diseases it is involved in. Learn about the diverse effects antiphospholipid antibody syndrome (APS) can have, from heart attack to miscarriage and how APS can be treated.
Antiphospholipid syndrome is an autoimmune disease, in which "antiphospholipid antibodies" (anticardiolipin antibodies and lupus anticoagulant) react against proteins that bind to anionic phospholipids on plasma membranes. Like many autoimmune diseases, it is more common in women than in men. The exact cause is not known, but activation of the system of coagulation is evident. Clinically important antiphospholipid antibodies (those that arise as a result of the autoimmune process) are associated with thrombosis and vascular disease. The syndrome can be divided into primary (no underlying disease state) and secondary (in association with an underlying disease state) forms. Anti-ApoH and a subset of anti-cardiolipin antibodies bind to ApoH, which in turn inhibits Protein C, a glycoprotein with regulatory function upon the common pathway of coagulation (by degradating activated factor V). Lupus anticoagulant (LAC) antibodies bind to prothrombin, thus increasing its cleavage to thrombin, its active ...
Antiphospholipid antibodies occur in various clinical states, including the primary antiphospholipid syndrome. Clinical features in these conditions appear to be caused by vasculopathy associated with the presence of these antibodies.. We report the case of a patient with primary antiphospholipid syndrome who experienced cardiac necrosis secondary to myocardial microvasculopathy in the absence of vasculitis. This case demonstrates unequivocally that noninflammatory myocardial microvasculopathy occurs in the primary antiphospholipid syndrome per se without any clinical or immunologic signs of systemic lupus erythematosus or other disease process. The histopathologic findings in the skin and myocardial biopsies showed a noninflammatory vasculopathy characterized by bland thrombi and lack of infiltration of the vessel wall by inflammatory cells. Ultrastructural examination of the myocardial biopsy confirmed the vascular thrombosis and endothelial activation and showed no deposits in basement ...
Antiphospholipid antibody syndrome should be suspected in a patient with unprovoked venous and arterial thromboses, especially in a young patient without provocation. Testing can also be considered in women with histories of pregnancy loss, intrauterine growth restriction, preeclampsia, and abruption in settings in which antiphospholipid syndrome is suspected (testing should be limited to lupus anticoagulant, anticardiolipin Ab, and beta 2 glycoprotein Ab). -Diagnosis is based on clinical criteria of thromboses or pregnancy morbidity in the presence of antiphospholipid antibodies. The antiphospholipid antibodies used in the Sapporo classification are anticardiolipin (IgG and IgM), anti-beta2-glycoprotein (IgG or IgM), and lupus anticoagulant. Repeat confirmatory laboratory testing of the above antiphospholipid antibodies should be confirmed ,= 12 weeks apart. -Remember that you need clinical features and laboratory features to diagnosis antiphospholipid antibody syndrome. Thus, there is no value ...
Objective: To investigate the prevalence and clinical correlates of anti-heparin platelet factor 4 antibodies (anti-HPF4) in SLE patients with and without antiphospholipid antibodies (aPL).. Methods: Sera and clinical data were obtained from the Hospital for Special Surgery Autoimmune Disease Registry for 78 aPL-positive and 91 aPL-negative SLE patients without heparin-induced thrombocytopenia (HIT). Controls were 90 blood donors of comparable age and sex. Sera were assayed for anti-HPF4, IgG/IgM antiphospholipid antibodies (APhL), and IgG/IgM-β2-glycoprotein 1 antibodies (anti-β2GP1). Serotonin release assays (SRAs) were performed for subjects with positive anti-HPF4.. Results: Positive anti-HPF4 was seen in 9% of aPL-positive SLE patients, 4% of aPL-negative SLE patients and 1% of controls (p-value = 0.026, aPL-positive SLE versus controls). Two of 12 subjects with positive anti-HPF4 had reactive SRAs. In SLE patients, anti-HPF4 significantly correlated with IgM APhL, IgM anti-β2GP1, and ...
TY - JOUR. T1 - Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin-associated thrombocytopenia [9]. AU - Holtan, Shernan G.. AU - Knox, S. K.. AU - Tefferi, Ayalew. PY - 2006/7. Y1 - 2006/7. UR - http://www.scopus.com/inward/record.url?scp=33745225893&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=33745225893&partnerID=8YFLogxK. U2 - 10.1111/j.1538-7836.2006.01961.x. DO - 10.1111/j.1538-7836.2006.01961.x. M3 - Article. C2 - 16839370. AN - SCOPUS:33745225893. VL - 4. SP - 1632. EP - 1634. JO - Journal of Thrombosis and Haemostasis. JF - Journal of Thrombosis and Haemostasis. SN - 1538-7933. IS - 7. ER - ...
OBJECTIVE: To characterize the clinical manifestations of patients with antiphospholipid antibody syndrome (APS) and pulmonary hemorrhage (PH). METHODS: We performed a retrospective, single-center analysis of patients with APS who were followed up fr
Home Care in Prior Lake MN: June is Antiphospholipid Antibody Syndrome Awareness Month, which was created to get people talking about the dangers this disease poses for people of all ages.
NorthShore encourages patients to utilize our medical library. Read our Antiphospholipid antibody syndrome encyclopedia resources online.
Amaduzzi, Francesco and Bontempo, Giovanni and Francolini, Giancarlo and Frausini, Gabriele (2009) Antiphospholipid antibody syndrome. Functional Neurology; New Trends in Interventional Neurosciences, 24 (S1). pp. 70-71. ISSN 1971-3274 ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Sneddons syndrome vasculopathy with antiphospholipid antibodies in a child
The antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPA) associated with thrombosis (arterial and venous) and pregnancy morbidity. This thesis has aimed to investigate the frequency of protein C pathway defects in patients with aPA and to study clinical correlates examine the mechanisms of antiphospholipid interference in the protein C pathway and to assess activated protein C (APC) resistance in patients with aPA in terms of thrombin generation. Although have I have discovered a high degree of heterogeneity in the phenotype of patients with APS, I have demonstrated APC resistance and increased thrombin generation in the majority of patients with APS. While in some cases, APC resistance is clearly immunoglobulin mediated, it is a multifactorial phenomenon with many confounding variables. My data suggest that immunoglobulin dependent APC resistance may occur through P2 glycoprotein-I dependent and independent mechanisms. In a detailed study of ...
Antiphospholipid syndrome is an autoimmune disease in which the body produces large amounts of antiphospholipid antibodies. Phospholipids are a special type of fat containing phosphate that makes up the outer walls of the bodys cells. Antiphospholipid antibodies attack the phospholipids. This causes many different problems including increased blood clotting. Cardiolipin is one type of phospholipid and specific anticardiolipin antibodies may develop.. This disease is about two times more common in women than men. It is generally characterized by the following:. ...
BACKGROUND Antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by vascular thrombosis (arterial or venous) and/or pregnancy complications associated with the occurrence of autoantibodies, specifically lupus anticoagulant, anticardiolipin antibodies, and/or anti-β2 glycoprotein-I antibodies confirmed at least twice over a 12 week period according to the 2006 Sydney criteria. Antiphospholipid antibodies are encountered in the general population with a reported prevalence of 1% to 5% However, APS is far more infrequent with a prevalence of 40-50/100,000 persons and an incidence of about 5 new patients/100,000 persons. APS can be diagnosed in patients with no apparent clinical or laboratory pathology (primary APS) or it may be related to numerous other conditions, autoimmune diseases (usually systemic lupus erythematosus), malignancies, infections and drugs (secondary APS). Women are at risk for APS since the disease is encountered in both the primary and the secondary state
Background: Antiphospholipid antibodies (aPL) are a heterogeneous family of anti-bodies associated with thrombosis and other complications. Objective: To study the prevalence of aPL in patients with thrombosis at Aleppo University Hospitals, Syria. Methods: One hundred and fifty-seven patients with venous and arterial thrombosis and 63 healthy controls were studied. Anticardiolipin antibodies (aCL) and Lupus antico-agulant (LA) were determined. Results: Thirty-four out of 157 (21.7%) patients with thrombosis had some type of aPL. aPL was also found in four healthy subjects (4/63=6.3%). Eighteen patients (11.5%) were positive for LA, 20 (12.7%) for aCL anti-bodies and 4 (2.6%) were positive for more than one aPL. Patients without risk factors for thrombosis and having positive aPL were 23/34 (67.7%). Fourteen out of 78 (17.9%) patients with arterial thrombosis, and 20/79 (25.3%) with venous thrombosis were positive for at least one aPL. Conclusion: Our study showed a significant preva-lence of aPL in
BACKGROUND AND OBJECTIVES:. Vascular disease is common in systemic lupus erythematosus (SLE) and patients with antiphospholipid antibodies (aPL) are at high risk to develop arterial and venous thrombosis. Since HLA class II genotypes have been linked to the presence of pro-thrombotic aPL, we investigated the relationship between HLA-DRB1 alleles, aPL and vascular events in SLE patients.. METHODS:. 665 SLE patients of Caucasian origin and 1403 controls were included. Previous manifestations of ischaemic heart disease, ischaemic cerebrovascular disease (ICVD) and venous thromboembolism (together referred to as any vascular events (AVE)) were tabulated. aPL were measured with ELISA. Two-digit HLA-DRB1 typing was performed by sequence-specific primer-PCR.. RESULTS: HLA-DRB1*04 was more frequent among SLE patients with ICVD compared to unaffected patients. This association remained after adjustment for known traditional cardiovascular risk factors. HLA-DRB1*13 was associated with AVE. All measured ...
Antiphospholipid syndrome is an autoimmune disease. This happens when your immune system fights against normal cells. This condition may also be called Hughes syndrome, sticky blood syndrome, and antiphospholipid antibody syndrome.
1. Yamaguchi Y, Noriyuki N, Kaburaki J, et al. Excesive exposure to aninic surfaces maitains autoantiboy response to B2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007;110:4312-18. 2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4:205-306. 3. Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J. 1983;287:1088-9.. 4. Alijotas-Reig J. Towards the comprehension of heterogeneity of clinical manifestations related to antiphospholipid antibodies. Med Clin (Barc) 2005;125:187-89. 5. Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic non-autoimmune women with unexplained recurrent primary early fetal loss. The Nimes Obstericians and Haematologists study-NOHA. Thromb Haemost 2000;84:228-236. 6. Asherson RA, Cervera R, Shepshelovich D, et al. Nonthrombotic manifestations ...
Definition of antiphospholipid antibodies. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. APS can present with a variety of clinical phenotypes, including thrombosis in the veins, arteries and microvasculature as well as obstetrical complications. The pathophysiological hallmark is thrombosis, but other factors such as complement activation might be important. Prevention of thrombotic manifestations associated with APS includes lifestyle changes and, in individuals at high risk, low-dose aspirin. Prevention and treatment of thrombotic events are dependent mainly on the use of vitamin K antagonists. Immunosuppression and anticomplement therapy have been used anecdotally but have not been adequately tested. Pregnancy morbidity includes unexplained recurrent early miscarriage, fetal death and late obstetrical manifestation such as pre-eclampsia, premature birth or fetal ...
By Kristin Bendikson, MD. When a woman has a miscarriage, she often feels isolated and alone. Miscarriages are more common than most people realize, however; and when women start talking with their friends, they often find that they are not alone in coping with this difficult experience.. A miscarriage-the early loss of a pregnancy-occurs in approximately 15 percent of all clinically recognized pregnancies. If all pregnancies are accounted for, the statistic is closer to 50 percent ending in a loss. The increase is due to the fact that many women dont even know they are pregnant and experience their period at the normal time or just a few days late. Sometimes a woman knows she is having a miscarriage because she has symptoms, which might include bleeding and cramping followed by the passage of the pregnancy. Other times a woman doesnt sense there is anything wrong at all, and she finds out that the pregnancy has stopped growing only when she sees her doctor for an ultrasound.. Its important ...
The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the main clinical features of venous and/or arterial thrombosis (intravascular blood clotting), thrombocytopenia, recurrent fetal loss, and moderate-to-high titers of antiphospholipid (aPL) antibodies, lupus anticoagulant, anti-cardiolipin antibodies, and anti-beta-2-glycoprotein I antibodies (refs 1-2). aPL antibodies are autoantibodies that react with negatively-charged phospholipids such as cardiolipin. They are often found in the sera of patients with systemic lupus erythematosus and related diseases and are typical for the development of secondary APS. The presence of antiphospholipid antibodies in patients with no other autoimmune disease is characteristic of primary APS. Anti-cardiolipin antibodies are found in 80-90% of patients with APS. However, the presence of anti-cardiolipin antibodies are not specific to APS, because these antibodies may be detected in other autoimmune diseases, following ...
Pulmonology Advisor offers the latest asthma, COPD, lung cancer, pneumonia news articles for pulmonologists and the healthcare community. Download the FREE app now.
Health related message boards offering discussions of numerous health topics including allergies, cancer, diabetes, heart disease, exercise, attention deficit disorder, diet, and nutrition.
Health related message boards offering discussions of numerous health topics including allergies, cancer, diabetes, heart disease, exercise, attention deficit disorder, diet, and nutrition.
A free diabetes, endocrinology and medical news article resource for endocrinologists and physicians. Endocrinology conference coverage and drug information.
Physician assistants and nurse practitioners use Clinical Advisor for updated medical guidance to diagnose and treat common medical conditions in daily practice.
Antiphospholipid syndrome is a systemic autoimmune disorder. It is usually defined as the clinical complex of vascular occlusion and ischaemic events occurring in patients who have circulating antiphospholipid antibodies. Pathology Patients hav...
The Antiphospholipid Syndrome (APS) is characterized by thrombosis and pregnancy loss, clinical events mediated by pathogenic anti-phospholipid autoantibodies (aPL). β2-glycoprotein I (β2GPI) is the major autoantigens recognized by aPL. β2GPI is a cationic protein that binds to negatively charged surfaces such as those of apoptotic cells. This feature may lead to two major events: i) immunization with β2GPI fosters the Fc-receptor-mediated uptake by antigen presenting cells of apoptotic material decorated with β2GPIand the activation ofβ2GPI-specific T cells which in turn provide help to β2GPI-specific B cells for the production of anti-β2GPI; ii) apoptotic bodies decorated with β2GPI can be opsonized by anti-β2GPI and shifted towards a pro-inflammatory clearance by macrophages; epitope spread can occur with the generation of autoimmunity against nuclear autoantigens. In the presence of a predisposing genetic background and of a particular cytokine environment (type I interferons), the ...
Also called Hughes syndrome, the results of antiphospholipid syndrome can be catastrophic for a pregnant woman. Learn about antiphospholipid syndrome symptoms and prognosis, as well as how it relates to pregnancy complications like miscarriage and premature birth.
A look at antiphospholipid antibody syndrome, what laboratory tests can support the diagnosis of this syndrome, what are the causes and how is it treated. ...
Background. According to revised classification criteria of true antiphospholipid antibody syndrome, at least one of three antiphospholipid antibodies should be present on two or more occasions at least 12 weeks apart. However, it can be inconvenient to perform follow-up tests with interval of 12 weeks. We investigated clinical application of follow-up tests with interval of 12 weeks. Method. Totals of 67, 199, and 332 patients tested positive initially for the lupus anticoagulants confirm, the anti- glycoprotein-I antibody, and the anti-cardiolipin antibody test, respectively, from Jan 2007 to Jul 2009. We investigated clinical symptoms of patients, follow-up interval, and results of each test. Results. Among patients with initial test positive, 1.5%-8.5% were subjected to follow-up tests at interval of more than 12 weeks. Among 25 patients with negative conversion in tests, patients with interval of more than 12 weeks showed clinical symptom positivity of 33.3%, which was higher than that of ...
A woman in her thirties suffered from lupus and antiphospholipid antibody syndrome (APS), an autoimmune, hypercoagulable disorder caused by antiphospholipid antibodies, which attack and damage tissues and cells and cause blood clots to form in the bodys arteries and veins. The woman took several anticoagulant medications as a result of a stroke she suffered at age 20. She suffered another stroke and was admitted to the hospital. She was treated at the hospital for approximately three months. About a month into her stay she underwent a kidney biopsy. After the kidney biopsy she was again administered blood-thinning therapy, including the medication Lovenox. Several days after the kidney biopsy, the woman suffered a large hemorrhage from the area of the biopsy kidney, which had become infected. As a result, the woman developed renal and respiratory failure, multiple abscesses, aspiration pneumonia, and other serious injuries and complications for which she continues to require inpatient treatment years
The classical clinical picture of the antiphospholipid syndrome (APS) is characterized by venous and arterial thromboses, fetal losses and thrombocytopenia, in the presence of antiphospholipid...
It is an object of the present invention to provide a reagent for assaying anti-phospholipid antibodies, which is excellent in long-term storage stability and enables an accurate diagnosis of syphilit
Erkan: Antiphospholipid Syndrome patients with vascular events generally receive life-long anticoagulation, despite the lack of high-quality data on the risk of recurrence and optimal duration of anticoagulation. Given that at least 50% of thrombotic events in aPL-positive patients have recognizable triggers, the possibility of discontinuing anticoagulation in highly selected patients exists, especially when the triggers are eliminated. However, discontinuation of anticoagulation is a critical decision that requires careful assessment of comorbidities, triggers, and residual thrombosis as well as patient education. The 13th International Congress on aPL Treatment Task Force recommended that "in cases of first venous event, low-risk aPL profile, and a known transient precipitating factor, anticoagulation could be limited to 3-6 months." Given the importance of this question, i.e., anticoagulation withdrawal in APS, the development of a multicenter clinical trial protocol to determine whether ...
Antiphospholipid antibody syndrome (APS) is an autoimmune disorder in which patients have autoantibodies to phospholipid-bound proteins (eg, beta2-glycoprotein I, prothrombin, annexin A5). The pathophysiology is not precisely known. Antiphospholipid Syndrome (APS) is an important recognised cause of acquired treatable thrombophilia. It is characterised by the core clinical manifestations of thrombosis in both venous and arterial circulation resulting in recurrent thrombotic […]. ...
BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial or venous thrombosis (or both) and/or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The prevalence is estimated at 40 to 50 cases per 100,000 people. The most common sites of thrombosis are cerebral arteries and deep veins of the lower limbs. People with a definite APS diagnosis have an increased lifetime risk of recurrent thrombotic events. OBJECTIVES: To assess the effects of antiplatelet or anticoagulant agents, or both, for the secondary prevention of recurrent thrombosis, particularly ischemic stroke, in people with antiphospholipid syndrome ...
The present study investigated: (a) the presence of antiphospholipid antibodies and (b) the obstetric outcome in healthy pregnant women showing false-positive TORCH-Toxoplasmosis, Other: syphilis, varicella-zoster, Rubella, Cytomegalovirus (CMV), and Herpes infections-results. Data from 23 singleton healthy pregnancies with false-positive TORCH results were collected. Each woman was systematically screened for TORCH IgG and IgM during the pre-conception assessment and/or at the beginning of pregnancy. In the presence of IgM positivity, when indicated (CMV, toxoplasmosis, rubella, herpes simplex virus), IgG avidity was evaluated and, if possible, polymerase chain reaction was performed on an amniotic fluid sample in order to distinguish between primary infection or false positivity ...
One of the challenges of managing patients with antiphospholipid syndrome is the prevention of rethrombosis (secondary prophylaxis). Risk stratification, i.e. traditional cardiovascular and thrombosis
This case may be coincidental or it may be that the plasminogen deficiency increased the thrombotic tendency of APS in this patient. , 1996). Biochemistry. 35(43), 1383313842. 3 Genetics of Antiphospholipid Syndrome Jesús Castro-Marrero, Eva Balada, Josep Ordi-Ros and Miquel Vilardell-Tarrés Systemic Autoimmune Diseases Research Unit, Vall dHebron University Hospital Research Institute Universitat Autónoma de Barcelona, Barcelona Spain 1. , 2006). The etiology of APS, however, is still unknown. pdf in Orphanet, INSERM MIM nº 107320). APS can involve almost any organ system, including a wide range of clinical manifestations. , 2008). 2011) Microparticles in hemostasis and thrombosis. Circ Res. 108(10), 1284-1297. Pangburn MK & Rawal N. (2002) Structure and function of complement C5 convertase enzymes. Biochem Soc Trans. 30(Pt 6), 1006-1010. Pennings MT, van Lummel M, Derksen RH, Urbanus RT, Romijn RA, Lenting PJ & de Groot PG. (2006) Interaction of beta2-glycoprotein I with members of the ...
Hi, I have often thromboses, so Im taking anticoagulants regularly. Doctors are having trouble diagnosing. Maybe I have antiphospholipid syndrome.
Antiphospholipid syndrome is a lifelong condition. Women need treatment. This will lower your chance of getting blood clots. It will also reduce your risk for problems such as stroke and miscarriage. Medicine can reduce your risk for blood clots, but they can still happen. Its important to follow your healthcare providers care plan and have tests done as often as he or she recommends. Support groups can help you meet other people with your condition. Ask your healthcare provider about support groups in your area. ...
Antiphospholipid syndrome is a lifelong condition. Women need treatment. This will lower your chance of getting blood clots. It will also reduce your risk for problems such as stroke and miscarriage. Medicine can reduce your risk for blood clots, but they can still happen. Its important to follow your healthcare providers care plan and have tests done as often as he or she recommends. Support groups can help you meet other people with your condition. Ask your healthcare provider about support groups in your area. ...
... - also known as Hughes syndrome - is an autoimmune disorder in which the immune system attacks phospholipids.
By combining fundamental research and monitoring a single cohort of kidney-transplant patients with antiphospholipid syndrome, the researchers have highlighted a beneficial effect of sirolimus, commonly used as an immunosuppressor in organ transplants, to prevent recurrence of vascular lesions on the transplanted kidney.
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
Reviews and ratings for bufferin arthritis strength when used in the treatment of antiphospholipid syndrome. Share your experience with this medication by writing a review.
Antiphospholipid Syndrome Clinical Research Trial Listings in Hematology Immunology Obstetrics/Gynecology (Womens Health) Rheumatology on CenterWatch
The European Medical Journal (EMJ) is an open-access, peer-reviewed medical journal. Founded in 2012 as an imprint of Gorely New Media, the European Medical Journal provides reviews, symposiums and developments from Europes medical congresses. Each journal is published six weeks after its relevant congress.
Do You Have Antiphospholipid Ant? Join friendly people sharing true stories in the I Have Antiphospholipid Ant group. Find support forums, advice and chat with groups who share this life experience.
The risk of hemorrhage is influenced by multiple factors in acute myeloid leukemia (AML). We investigated whether hemorrhage in AML patients was associated with endothelial perturbation, potentially caused by thrombocytopenia, platelet dysfunction and leukocytosis. Biomarkers of endothelial perturbation, coagulation and platelet activation were analyzed in 49 AML patients, along with previously collected data on bleeding status and platelet activation markers. High levels of syndecan-1, a marker of endothelial glycocalyx degradation, were associated with bleeding, impaired platelet function, higher age, endothelial cell activation and damage, and leukocytosis. We suggest that platelet dysfunction and leukocytosis in AML causes endothelial perturbation ...
Glycemia and insulinemia in healthy subjects after lactose-equivalent capacity to stimulate insulin release of foods: the insulin demand generated Which test strips can you use with the free meter? OneTouch Verio Test Strips Around 3.7 million people in the UK have diabetes yet according to Diabetes UK One or both eyes may be affected. Diabetes Blood Test Results That means type 2 medication treatment solutions are big line of work. Tilda Rizazz Rice health Concern On Your Mind? Diabetic Rash On Legs ::The 3 Step Trick that Reverses Diabetes Permanently in As Little as 11 Days. Systemic lupus erythematosus (SLE) Pancreatitis in lupus is uncommon and could occur in a setting of high SLEDAI scores antiphospholipid antibody syndrome Diabetes Care Pathway NICE for the management of diabetes for patients with type 2 diabetes that may have been avoided NovoRapid vials prefilled pens (FlexPen and Flextouch pens) and penfill cartridges (for use with NovoPens) all contain the active ingredient insulin ...
Founded in 2005, APS Foundation of America, Inc. (APSFA) is the only United States nonprofit health agency dedicated to bringing national awareness to Antiphospholipid Syndrome (APS), the major cause of multiple miscarriages, thrombosis, young strokes and heart attacks. We are a volunteer run, community based 501(c)3 non-profit Public Charity organization and is dedicated to fostering and facilitating joint efforts in the areas of education, support, public awareness, research and patient services. The APSFAs Medical Advisory Team includes nationally & internationally recognized experts on Antiphospholipid Syndrome.. APS is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. There are two known forms. APS may occur in people with systemic lupus erythematosus, other autoimmune disease, or in otherwise healthy individuals.. APS is also referred to as APLS or APLA in the United ...
And given that that progestin-releasing IUDs do not increase the risk for blood clots [ref 1], it is a particularly attractive option in women with a history of blood clots (DVT, PE, etc) or a clotting disorder (= thombophilia or hypercoagulable states), such as factor V Leiden, the prothrombin (factor II) mutation, or protein C, S or antithormbin deficiency or the antiphospholipid antibody syndrome. Thrombosis is not listed as a possible adverse outcome associated with Skyla® use ...
Is there anyone in here with a child who has Antiphospholipid Antibody Syndrome? My daughter was diagnosed at age 10. Now shes almost 12. It would just be nice...
Hello ladies. It has been quite a while since my last post. My little boy Malcolm is now 6, and my angel baby Amelia would be 7 now. (It is hard to believe how the time has gone by.) Here is my question. I had PE with elevated liver enzymes and my bps got up to 200ish/100+. This was in 2004. I was eventually diagnosed with antiphospholipid antibody syndrome and I now take warfarin daily. After PE, I did not apparently have any lasting damage to my eyes, liver, etc. But Ive had a couple of weird episodes in the last few years involving shortness of breath, a feeling of pain in my chest, arms, and collar bone, and general malaise. THe last episode was a couple of days ago and I went to the ER. Ive now had EKGs a couple of times, which show no abnormality with my heart. The chest CT showed no lung blood clot. Frankly, I have been convinced both times I was having a heart attack - totally relieved that wasnt the issue, but it is perplexing ...
When conducting a comprehensive survey of spouses for habitual miscarriage, the first task of a specialist is to assess congenital factors predisposing to the development of high-risk thrombophilia.. - A blood test of spouses for compatibility with the HLA Class II system is also being conducted. We will explain a little. Immune mechanisms are involved in the development of recurrent miscarriage. Each person is unique in the set of HLA-determinants (tissue compatibility system). For the normal course of pregnancy, an important factor is the maximum difference between parents in the histocompatibility analysis. If this indicator is normal, then other risk factors are assessed.. - During the examination, a blood test is also assigned for the diagnosis of antiphospholipid syndrome (APS), a test for lupus anticoagulant (BA). Antiphospholipid antibodies have a direct damaging effect on the ovum with a further development of spontaneous abortion. The complex for the diagnosis of APS includes an ...
Introduction The aim of this study was to examine the prevalence and functional effects of antibodies directed against Factor (F)Xa and other serine proteases (SP) in patients with antiphospholipid...
Dont be scared! There a a lot of us walking around with these antiphospholipid antibodies that never affect our health. It isnt known why in maybe a third of us that has them they suddenly play up. They can even appear in pregnancy and disappear afterwards. Either the anticardiolipin tests or the lupus anticoagulant can be positive at any time or negative. Thats why both tests are usually done together. Levels can vary too just as the body goes about its normal business so both tests need to be done at an interval of at least 6-8 weeks to see if they are constantly present and at what levels. They are not always due to autoimmune disease either. Leverls can be abnormal in infectious or other diseases so often certain tests are also done which indicate if they are autoimmune in ...
Anti-phospholipid antibody syndrome (aPL) is a condition that promotes the formation of blood clots. In this disorder, a person may have miscarriages, unexplained blood clots in the veins or arteries (resulting in heart attack, a venous blood clot, or stroke), or a decreased platelet count.. This disorder is determined by blood tests. There is no single blood test for this disorder, a variety of different antibody measurements are made to diagnose this condition. Sometimes this disorder is associated with systemic lupus erythematosus (SLE).. People with clinical symptoms of blood clots may be treated with several medications, including heparin (or low molecular weight heparin), warfarin, or aspirin. The duration of therapy may depend on the number of clinical events they have experienced and the efficacy of these medications.. ...
Doruk Erkan and colleagues studied rituximab in antiphospholipid syndrome. "The primary objective of this pilot, open-label, Phase II study was to evaluate the safety of rituximab in 20 aPL-positive patients, as assessed by serious and non-serious adverse events (AE) (up to 12 months [m])." Two patients out of 19 developed infusion reactions, which I think is a high number; the study does not reflect about the issue of a special risk. They counted 59 AEs (12 serious with hospitalizations, but interpreted these as "unlikely" to be related to rituximab, 7 non-serious within 48h of infusion were interpreted as "likely". Even if unrelated to rituximab is correct, Ive never seen as many AEs, especially with hospitalization is my own patients (rheumatoid arthritis), so I think that this is another hint to look into special risks for aPL-positive patients treated with rituximab. There were some effects on aPL-tests, but not convincing as the largest effects are in the smallest groups (down to n=2). In ...
Sindroma Antiphospholipid (APS) - eshte nje semundje autoimmune karakterizuar nga perpunimin e sasive te medha te antitrupave me fosfolipide - strukturat kimike të cilat janë ndërtuar të qelizave...
Objective To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts. Methods The HepASA Trial was an RCT including patients with a history of RPL and at least 1 of the following: antiphospholipid antibody (aPL), an inherited thrombophilia, or antinuclear antibody. Treatment groups were stratified by aPL status and history of early versus late pregnancy losses. Patients received either LMWH/ASA or ASA alone. The primary outcome was live birth; secondary outcomes included adverse events and bone loss at the spine and femoral neck. Literature over the past 20 years was reviewed to identify comparable RCT. Results Over 4 years, 859 women with RPL were screened: 88 (10.2%) fulfilled inclusion criteria, became pregnant and were randomized to receive ...
For decades, scientists and clinicians have been puzzled by an autoimmune condition, antiphospholipid syndrome (APS), which causes devastating health problems including uncontrolled blood clots and repeated pregnancy loss. Recent studies have shown that naturally produced antibodies that bind to phosphatidylethanolamine (PE) are positively correlated to antiphospholipid syndrome.. Phosphatidylethanolamine (PE), a lipid that makes up 20% of the inner cell membrane, has roles in membrane trafficking and reorganization. Paradoxically, the antibodies that bind to PE (anti-PE antibodies) in APS patients are produced outside of cells. This raises the question of how do the anti-PE antibodies bind to PE without having access to their targets? To unravel this mystery, Chemistry of Life Processes Institute faculty member and Northwestern Medicine investigator Ming Zhao (cardiology) synthesized special molecular probes to investigate the dynamic distribution of PE in living cells under the microscope. The ...
In those with APS, the immune system fails to recognize certain blood proteins, attacking and destroying them as if they were bacteria or viruses. The destruction of these cells causes blood clots to form which can occur anywhere in the body. These clots can cause serious damage to cells and tissue depending on where they form and can break free, traveling anywhere in the body through the circulatory system. APS can also cause several complications during pregnancy. Though it is possible to have APS alone, a condition known as primary APS, many with the condition also suffer from rheumatic diseases such as lupus. When APS accompanies other disorders, it is known as secondary APS. Anyone can be affected by APS, but the disease is much more likely to affect women, with between 75 and 95 percent of those with APS being female. A higher incidence of APS is reported among African-American and Hispanic populations as well, although the reasons for this are unknown. The disorder has been recorded in ...
This disease can have serious effects in pregnancy, both for the mother and the baby. These include strokes, blood clots, and recurrent miscarriage.
APS may contribute to an increased frequency of stroke or MI, especially in younger individuals. Strokes may develop secondary to in situ thrombosis or embolization that originates from the valvular l... more
I have APS. I was diagnosed in July 2011 after losing my son, Fritzy, on May 6th to PE and HELLP. I was 24 weeks along at the time. I started taking LDA immediately after my diagnosis because I wanted to conceive sooner than later because I was 38 at the time. In November 2011, I becamel pregnant. At 8 weeks I saw my MFM and started 40 mg twice daily lovenox. My due date was August 21. My pregnancy was very normal. My doctors were pleased at how things went. My pressures were excellent, never any protein, and only swelling in my feet at the end. I was scheduled to be induced the 39th week but Gavin came at 37 +4. He was beautiful and healthy. He is almost 18 weeks old and an absolute joy. I would suggest looking on the internet to learn more. I had the most luck with the Hughes Syndrome page. I plan to resume taking LDA when I finish breastfeeding, just as a preventive measure. Hope that was helpful ...
If your current repository username differs from your University username, please email [email protected] so we can update these details on your behalf.. Due to the change, there will be a short outage of the repository from 9am on the morning of the 1st of November. ...
Principal Investigator:TSUTSUMI Akito, Project Period (FY):1997 - 1999, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:内科学一般
Build: Wed Jun 21 18:33:50 EDT 2017 (commit: 4a3b2dc). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
TY - JOUR. T1 - Bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome, successfully treated with thrombolysis. AU - Chamsi-Pasha, Mohammed A.. AU - Alyousef, Tareq. AU - Sayyed, Samer H. PY - 2014/1/1. Y1 - 2014/1/1. N2 - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly limited. We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months after valve replacement, and successfully treated with thrombolytic therapy. (Echocardiography 2014;31:E278-E281).. AB - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly ...
A 51-year-old man gave a 2-year history of worsening mobility, cognitive decline and headaches. He had a history of thromboembolic stroke, recurrent transient ischaemic attacks and a spontaneous intraventricular haemorrhage. On examination, he had livedo reticularis and perniosis and a systolic murmur. Catheter cerebral angiography showed peripheral small-vessel and medium-vessel vasculopathy resulting in pruning of the distal cortical vessels and tortuous irregular distal collaterals. Skin biopsy showed subtle vasculopathy with ectasia of capillaries and postcapillary venules but no frank vasculitis or arterial thrombosis. Repeated serum antiphospholipid antibody titres were negative. The clinical features, skin biopsy and angiogram findings strongly supported a diagnosis of Sneddons syndrome. Clinicians should consider Sneddons syndrome in patients with livedo reticularis and stroke. There are treatment dilemmas in this situation when ischaemic and haemorrhagic cerebral events coexist. ...
Looking for online definition of anticardiolipin antibody syndrome in the Medical Dictionary? anticardiolipin antibody syndrome explanation free. What is anticardiolipin antibody syndrome? Meaning of anticardiolipin antibody syndrome medical term. What does anticardiolipin antibody syndrome mean?
Anticardiolipin antibodies (aCL) derived from the sera of individuals exhibiting the antiphospholipid syndrome (APS) directly bind to beta 2-glycoprotein I (beta 2-GPI), which is adsorbed to an oxidized polystyrene surface. Oxygen atoms were introduced on a polystyrene surface by irradiation with electron or gamma-ray radiation. X-ray photoelectron spectroscopy revealed the irradiated surfaces were oxidized to generate C-O and C = O moieties. aCL derived from either APS patients or (NZW x BXSB)F1 mice bound to beta 2-GPI coated on the irradiated plates, depending on the radiation dose. Antibody binding to beta 2-GPI on the irradiated plates was competitively inhibited by simultaneous addition of cardiolipin (CL)-coated latex beads mixed together with beta 2-GPI but were unaffected by addition of excess beta 2-GPI, CL micelles, or CL-coated latex beads alone. There was a high correlation between binding values of aCL in sera from 40 APS patients obtained by the anti-beta 2-GPI enzyme-linked ...
Looking for online definition of livedo reticularis with summer ulceration in the Medical Dictionary? livedo reticularis with summer ulceration explanation free. What is livedo reticularis with summer ulceration? Meaning of livedo reticularis with summer ulceration medical term. What does livedo reticularis with summer ulceration mean?
A prospective study of IgG and IgM isotypes of anticardiolipin antibodies (aCL) in a series of 100 patients with systemic lupus erythematosus was carried out. To determine the normal range of both isotype titres a group of 100 normal control serum samples was studied and a log-normal distribution of IgG and IgM isotypes was found. The IgG anticardiolipin antibody serum was regarded as positive if a binding index greater than 2.85 (SD 3.77) was detected and a binding index greater than 4.07 (3.90) was defined as positive for IgM anticardiolipin antibody. Twenty four patients were positive for IgG aCL, 20 for IgM aCL, and 36 for IgG or IgM aCL, or both. IgG aCL were found to have a significant association with thrombosis and thrombocytopenia, and IgM aCL with haemolytic anaemia and neutropenia. Specificity and predictive value for these clinical manifestations increased at moderate and high anticardiolipin antibody titres. In addition, a significant association was found between aCL and the ...
Pregnancies in women with systemic lupus erythematosus are recognized to result in excessive fetal morbidity and mortality. Maternal autoantibody status may explain some of these problems. Anti-cardiolipin antibody has been associated with recurrent pregnancy losses in some women with lupus, but the risk of these losses has not been defined. At...
A child with terminal deletion of the long arm of the Y chromosome (Yq--) presented with marked livedo reticularis, snub nose, microcephaly, short stature, and other dysmorphic features. He was profoundly mentally retarded. Most of the patients with Yq- have been reported as having varying dysmorphic features, mental retardation, and short stature. This child, in addition to the above, has livedo reticularis and microcephaly. He was of normal birthweight and, therefore, does not come into the syndrome of microcephaly, snub nose, livedo reticularis, and low birthweight dwarfism. Further information on Yq- should be obtained to ascertain if consistent patterns of abnormalities exist.. ...

PatientsLikeMe | Antiphospholipid antibody syndrome symptoms, treatments & patient forums | PatientsLikeMePatientsLikeMe | Antiphospholipid antibody syndrome symptoms, treatments & patient forums | PatientsLikeMe

640 patients with antiphospholipid antibody syndrome experience fatigue, Pain, depressed mood, anxious mood, and insomnia and ... Find the most comprehensive real-world symptom and treatment data on antiphospholipid antibody syndrome at PatientsLikeMe. ... and Oxycodone to treat their antiphospholipid antibody syndrome and its symptoms. ... What is antiphospholipid antibody syndrome?. Antiphospholipid syndrome, Hughes syndrome, or antiphospholipid antibody syndrome ...
more infohttps://www.patientslikeme.com/conditions/515-antiphospholipid-antibody-syndrome

Antiphospholipid antibody syndrome - Oncology Nurse AdvisorAntiphospholipid antibody syndrome - Oncology Nurse Advisor

"Antiphospholipid antibodies-we are not quite there yet". Blood Reviews. vol. 25. 2011. pp. 97-106. (Nice overview of antibody ... Overview of APS, with details on drug-related antibodies.). Pham, C, Shen, YM. "Antiphospholipid antibodies and malignancy". ... "Antiphospholipid syndromes in infectious diseases". Hematol Oncol Clin N Am. vol. 22. 2008. pp. 131-144. (Discusses antibodies ... Weinstein, S, Piette, W. "Cutaneous manifestations of antiphospholipid antibody syndrome". Hematol Oncol Clinics N Am. vol. 22 ...
more infohttps://www.oncologynurseadvisor.com/home/decision-support-in-medicine/dermatology/antiphospholipid-antibody-syndrome-2/

Systemic Antiphospholipid Antibody Syndrome, Antiphospholipid Antibody Syndrome, APS, APLS, Hughes Syndrome, Sticky Blood,...Systemic Antiphospholipid Antibody Syndrome, Antiphospholipid Antibody Syndrome, APS, APLS, Hughes Syndrome, Sticky Blood,...

Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid ... These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [ ... Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - ... These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [ ...
more infohttp://apls.freelinuxhost.com/html/demyelination.html

Sneddons syndrome: it is all in the ectoderm | Practical NeurologySneddon's syndrome: it is all in the ectoderm | Practical Neurology

Repeated serum antiphospholipid antibody titres were negative. The clinical features, skin biopsy and angiogram findings ...
more infohttp://pn.bmj.com/content/16/4/300

Antiphospholipid antibodies definition | Drugs.comAntiphospholipid antibodies definition | Drugs.com

Definition of antiphospholipid antibodies. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and ... antiphospholipid antibodies. Definition: antibodies directed against phosphorylated polysaccharide esters of fatty acids, ... includes lupus anticoagulant, Venereal Disease Research Laboratories, and anticardiolipin antibodies. Associated with immune- ...
more infohttps://www.drugs.com/dict/antiphospholipid-antibodies.html

Antiphospholipid AntibodiesAntiphospholipid Antibodies

... and what the results of antiphospholipid antibody testing might mean ... Describes how antiphospholipid antibody tests are used, when they are requested, ... Antiphospholipid antibody testing is used to help determine the cause of:. Antiphospholipid antibody testing is used to help ... The most common antiphospholipid antibodies are cardiolipin antibodies (also called anticardiolipin antibodies or ACA) and the ...
more infohttps://www.labtestsonline.org.uk/tests/antiphospholipid-antibodies

Antiphospholipid Antibody Linked to First MIAntiphospholipid Antibody Linked to First MI

The case-control PAROKRANK study identified a strong association between an anticardiolipin antibody and MI, but also raises a ... Because antiphospholipid antibodies (aPLs) can come and go or increase and decrease, "it could be that the antibodies are a ... Cite this: Antiphospholipid Antibody Linked to First MI - Medscape - Oct 23, 2018. ... Those results showed that patients with MI had antibodies to fewer domains, mainly domains IV and V, while antibodies from ...
more infohttps://www.medscape.com/viewarticle/903832

Antiphospholipid antibody markersAntiphospholipid antibody markers

... , including how long the results take, specimen requirements and who to contact if you have a ... Home Our services Haemostasis and thrombosis centre Diagnostic haemostasis laboratories Antiphospholipid antibody markers ... IgG, IgM & IgA Anticardiolipin antibodies.. (IgG and IgM anti-beta2-glycoprotein 1 antibodies are available by special ... Antiphospholipid markers are available during routine hours. Requests for urgent results or tests out of routine hours must be ...
more infohttps://www.guysandstthomas.nhs.uk/our-services/haemostasis-thrombosis/diagnostic-laboratories/Antiphospholipid-antibody-markers.aspx?ContensisTextOnly=true

Antiphospholipid Antibodies: Reference Range, Collection and Panels, BackgroundAntiphospholipid Antibodies: Reference Range, Collection and Panels, Background

... antibodies are group of antibodies directed against epitopes on plasma proteins that are uncovered by binding of these proteins ... The most commonly used tests to detect APL include lupus anticoagulant (LAC), anticardiolipin (ACL) antibodies, and anti-β2 - ... encoded search term (Antiphospholipid Antibodies) and Antiphospholipid Antibodies What to Read Next on Medscape. Related ... Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. ...
more infohttps://emedicine.medscape.com/article/2116457-overview

Antiphospholipid antibody syndrome | NorthShoreAntiphospholipid antibody syndrome | NorthShore

Read our Antiphospholipid antibody syndrome encyclopedia resources online. ... Antiphospholipid antibody syndrome. Antiphospholipid antibody syndrome is a blood-clotting disorder that makes the blood clot ... Antiphospholipid antibody syndrome is caused by antibodies. The body normally makes antibodies that attack a dangerous ... A person who has these antibodies and has had blood clots is said to have antiphospholipid antibody syndrome. ...
more infohttps://www.northshore.org/healthresources/encyclopedia/encyclopedia.aspx?DocumentHwid=tn9986

Antiphospholipid Antibodies (blood) - Marilyn GlenvilleAntiphospholipid Antibodies (blood) - Marilyn Glenville

Antiphospholipid antibodies (APAs) are the most common kind of abnormal immune system problem. Up to 15 per cent of women with ... Some women, however, produce APA blood-clotting antibodies which attack cells that build the placenta and increase the risk of ... Home∕Tests∕ Antiphospholipid Antibodies (blood). Antiphospholipid Antibodies (blood). Womens Health Issues. *Breast Problems* ...
more infohttps://www.marilynglenville.com/tests/antiphospholipid-antibodies/

APLA - Antiphospholipid Antibody (syndrome) | AcronymFinderAPLA - Antiphospholipid Antibody (syndrome) | AcronymFinder

APLA stands for Antiphospholipid Antibody (syndrome). APLA is defined as Antiphospholipid Antibody (syndrome) frequently. ... Lupus anticoagulant, antiphospholipid syndrome and cardiac surgery. Antiphospholipid antibody syndrome manifesting as a deep ... Antiphospholipid antibody levels of Henoch-Schonlein purpura patients and controls HSP HSP Control active remission (n=30) ... The antiphospholipid antibody syndrome (APLS) is the most important treatable cause for recurrent miscarriage. ...
more infohttps://www.acronymfinder.com/Antiphospholipid-Antibody-

Antiphospholipid antibody syndrome Archives - ProhealthAntiphospholipid antibody syndrome Archives - Prohealth

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. ...
more infohttps://www.prohealth.com/library/disease/antiphospholipid-antibody-syndrome

PRIME PubMed | Calciphylaxis in catastrophic antiphospholipid antibody syndromPRIME PubMed | Calciphylaxis in catastrophic antiphospholipid antibody syndrom

PubMed journal article Calciphylaxis in catastrophic antiphospholipid antibody syndrom were found in PRIME PubMed. Download ... "Calciphylaxis in Catastrophic Antiphospholipid Antibody Syndrome." Blood Coagulation & Fibrinolysis : an International Journal ... Calciphylaxis in catastrophic antiphospholipid antibody syndrome.. Blood Coagul Fibrinolysis 2015; 26(4):467-8BC ... Shah S, Larson A, Datta Y. Calciphylaxis in Catastrophic Antiphospholipid Antibody Syndrome. Blood Coagul Fibrinolysis. 2015;26 ...
more infohttps://www.unboundmedicine.com/medline/citation/25688465/Calciphylaxis_in_catastrophic_antiphospholipid_antibody_syndrome_

Inter-assay variation in antiphospholipid antibody testing: Ingenta ConnectInter-assay variation in antiphospholipid antibody testing: Ingenta Connect

We evaluated inter-assay variation in anticardiolipin antibody status, comparing three centres, and using different assays ...
more infohttp://www.ingentaconnect.com/content/bsc/bjo/2002/00000109/00000003/art00014

Antiphospholipid antibody - definition of Antiphospholipid antibody by The Free DictionaryAntiphospholipid antibody - definition of Antiphospholipid antibody by The Free Dictionary

Antiphospholipid antibody synonyms, Antiphospholipid antibody pronunciation, Antiphospholipid antibody translation, English ... dictionary definition of Antiphospholipid antibody. abbreviation for Associate of the Institute of Chartered Accountants ... Related to Antiphospholipid antibody: Antiphospholipid antibody syndrome. ACA. abbreviation for (Accounting & Book-keeping) ... Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome.. A case report of antiphospholipid ...
more infohttps://www.thefreedictionary.com/Antiphospholipid+antibody

Antiphospholipid Antibodies and Early Severe Preeclampsia. - Full Text View - ClinicalTrials.govAntiphospholipid Antibodies and Early Severe Preeclampsia. - Full Text View - ClinicalTrials.gov

Antiphospholipid Syndrome. Autoimmune Diseases. Immune System Diseases. Antibodies. Immunoglobulins. Antibodies, ... Antiphospholipid Antibodies and Early Severe Preeclampsia.. The safety and scientific validity of this study is the ... Antiphospholipid Antibodies and Early Severe Preeclampsia (, 34 Weeks of Gestation). A Case-Control Study.. ... The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT01538121?term=severe+preeclampsia+AND+weeks+of+gestation&rank=1

Antiphospholipid antibodies | definition of antiphospholipid antibodies by Medical dictionaryAntiphospholipid antibodies | definition of antiphospholipid antibodies by Medical dictionary

What is antiphospholipid antibodies? Meaning of antiphospholipid antibodies medical term. What does antiphospholipid antibodies ... Looking for online definition of antiphospholipid antibodies in the Medical Dictionary? antiphospholipid antibodies explanation ... Anti-phospholipid syndrome is a disorder of the immune system, where abnormal antibodies, called antiphospholipid antibodies ( ... antiphospholipid antibodies. an·ti·phos·pho·lipid an·ti·bod·ies. antibodies directed against phosphorylated polysaccharide ...
more infohttps://medical-dictionary.thefreedictionary.com/Antiphospholipid+antibodies

Update on Antiphospholipid Antibody Syndrome Management | IntechOpenUpdate on Antiphospholipid Antibody Syndrome Management | IntechOpen

Update on Antiphospholipid Antibody Syndrome Management , IntechOpen, Published on: 2012-04-20. Authors: Rocco Manganelli, ... Update on Antiphospholipid Antibody Syndrome Management. By Rocco Manganelli, Salvatore Iannaccone, Serena Manganelli and Mario ... Medicine » Immunology, Allergology and Rheumatology » Antiphospholipid Syndrome, book edited by Alena Bulikova, ISBN 978-953- ...
more infohttps://www.intechopen.com/books/antiphospholipid-syndrome/update-on-antiphospholipid-syndrome-antibody-management/

Lupus anticoagulants and antiphospholipid antibodies | University of Maryland Medical CenterLupus anticoagulants and antiphospholipid antibodies | University of Maryland Medical Center

Lupus anticoagulants and antiphospholipid antibodies. Toggle: English / Spanish Definition. Lupus anticoagulants are antibodies ... Antibodies to beta-2-glypoprotein I (Beta2-GPI). Your health care provider may check for antiphospholipid antibody syndrome ( ... ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS) In general, you will need long-term treatment with a blood thinner for a long time if ... The antiphospholipid antibodies (aPL) cause the tests to be abnormal in the laboratory. ...
more infohttps://www.umm.edu/Health/Medical/Ency/Articles/Lupus-anticoagulants

The management of thrombosis in the antiphospholipid-antibody syndrome.  - PubMed - NCBIThe management of thrombosis in the antiphospholipid-antibody syndrome. - PubMed - NCBI

Thrombosis in the antiphospholipid-antibody syndrome. [N Engl J Med. 1995]. *Answers to the antiphospholipid-antibody syndrome? ... Thrombosis in the antiphospholipid-antibody syndrome. [N Engl J Med. 1995]. *Thrombosis in the antiphospholipid-antibody ... Thrombosis in the antiphospholipid-antibody syndrome. [N Engl J Med. 1995]. *Thrombosis in the antiphospholipid-antibody ... The management of thrombosis in the antiphospholipid-antibody syndrome.. Khamashta MA1, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/7885428?dopt=Abstract

Graves Disease Associated with Cerebrovascular Disease and Antiphospholipid Antibody SyndromeGraves' Disease Associated with Cerebrovascular Disease and Antiphospholipid Antibody Syndrome

Graves Disease Associated with Cerebrovascular Disease and Antiphospholipid Antibody Syndrome. Ines Khochtali,1 Nadia Hamza,1 ... in this paper, we describe the case of a patient with Graves disease, who developed strokes with antiphospholipid antibodies ... which are favoured by a simultaneous presence of antiphospholipid antibodies syndrome. ...
more infohttps://www.hindawi.com/journals/ije/2010/624152/abs/

Catastrophic Antiphospholipid Antibody Syndrome - ONACatastrophic Antiphospholipid Antibody Syndrome - ONA

Antiphospholipid Antibody Syndrome. *Serum HPV Antibody Levels May Be a Biomarker for Recurrent HPV-associated Oropharyngeal ... Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening complication of antiphospholipid antibody syndrome with (a ... laboratory confirmation of antiphospholipid antibodies (aPL): lupus anticoagulant (LA) test; anticardiolipin antibody (aCL) by ... Sapporo criteria for antiphospholipid antibody syndrome (APS). Definite APS if at least one clinical and one laboratory ...
more infohttp://www.oncologynurseadvisor.com/critical-care-medicine/catastrophic-antiphospholipid-antibody-syndrome/article/587057/

Antiphospholipid Antibody Syndrome (APS) Awareness Month | HolidaySmartAntiphospholipid Antibody Syndrome (APS) Awareness Month | HolidaySmart

June is Antiphospholipid Antibody Syndrome (APS) Awareness Month. APS is a disorder that causes clotting events and can lead to ... June is Antiphospholipid Antibody Syndrome (APS) Awareness Month. APS is a disorder that causes clotting events and can lead to ...
more infohttps://www.holidaysmart.com/holidays/monthly/june/antiphospholipid-antibody-syndrome-aps-awareness-month

British Library EThOS: Antiphospholipid antibodies and the protein C pathwayBritish Library EThOS: Antiphospholipid antibodies and the protein C pathway

The antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPA) associated with ... of protein C pathway defects in patients with aPA and to study clinical correlates examine the mechanisms of antiphospholipid ...
more infohttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.498607
  • This preliminary proposal requires 4 manifestations, including at least 1 of 11 clinical manifestations and at least 1 of 6 immunologic manifestations (antinuclear antibody, anti-DNA, anti-Sm, antiphospholipid antibody , low complement, direct Coombs test), or lupus nephritis with positivity in either an antinuclear antibody or anti-DNA test. (thefreedictionary.com)
  • It could be an early reaction or it could be an isotype spread like you see with anti-citrullinated antibodies in rheumatoid arthritis with antibodies, but again we don't know," Svenungsson said. (medscape.com)
  • For the future, I think we need to look at temporal relationships between these antibodies and events. (medscape.com)
  • But we don't really know the temporal relationship between antibodies and events and if there is a class that switch from IgM to IgG, like you see in infections. (medscape.com)
  • The routine use of rituximab cannot be recommended as the single series published to date interestingly reported no reduction in antiphospholipid antibody titer and only improvement in some but not all non-criteria manifestations of APS. (thefreedictionary.com)